Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1359 (LINC01359) is a long intergenic non-coding RNA (lincRNA), defined as an autonomously transcribed RNA longer than 200 nucleotides that does not overlap with protein-coding genes. LINC01359, like other lincRNAs, does not encode a protein but may function in gene regulatory processes such as chromatin remodeling, fine-tuning the expression of adjacent genes, and influencing tissue-specific gene networks. While most biological functions of LINC01359 remain to be fully elucidated, lincRNAs as a molecular class play important roles in normal physiology, gene regulation, and diseases (notably various cancers). LINC01359 in particular has been reported to be associated with immune cell-related signatures in certain cancer studies; however, there are currently no approved drugs targeting it, nor is it a recognized therapeutic target. Key context and supporting details: - LINC01359 is listed as a long non-coding RNA gene in relevant genomics databases, including GeneCards, under the full name "Long intergenic non-protein coding RNA 1359"[1]. - LincRNAs (long intergenic non-coding RNAs) are a subclass of long non-coding RNAs, generally over 200 nucleotides, and do not overlap protein-coding genes[3][5][7]. - They can regulate gene expression at multiple levels, sometimes in cis (locally) or in trans (distant), act as molecular scaffolds for chromatin-modifying complexes, or influence cell type–specific transcriptional programs[3][5][7]. - While many lincRNAs are being studied for their disease roles, only a minority have well-established direct functions; for LINC01359, the literature indicates putative association with immune infiltrates in cancer but not a validated therapeutic or biomarker role[4]. - There are currently no drugs targeting LINC01359, and it is not categorized as an enzyme, transporter, receptor, or similar canonical drug target; its primary molecular classification is as a non-coding RNA[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1359 (LINC01359).